Review
Pharmacology & Pharmacy
Hang Sun, Huayu Yang, Yilei Mao
Summary: Hepatocellular carcinoma (HCC) is a highly prevalent and fatal cancer, with limited treatment options due to late-stage diagnosis and drug resistance. Targeted therapies, such as Sorafenib and tyrosine kinase inhibitors, have shown some benefits in HCC patients. However, the disease's heterogeneity and resistance remain significant challenges. The development of patient-derived preclinical models and personalized treatment strategies offer opportunities for improved outcomes.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Shun Ishido, Kaoru Tsuchiya, Yoshihito Kano, Yutaka Yasui, Kenta Takaura, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Urara Sakurai, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi
Summary: The clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma (HCC) who received multiple systemic therapies is investigated in this study. Gene alterations were detected in all nine patients, with seven being eligible for clinical trials based on CGP results. The median number of alterations per patient was four, and blood samples were used in patients with extrahepatic metastasis. These findings provide genomic information of patients with multiple systemic therapies and highlight the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the study suggests that understanding the genomic status in patients treated with multiple molecular-targeted agents could lead to the development of newer systemic agents for HCC treatment.
Article
Medicine, Research & Experimental
Ming Wu, Zijin Luo, Zhixiong Cai, Qianqian Mao, Zhenli Li, Hao Li, Cao Zhang, Yuting Zhang, Aoxue Zhong, Liming Wu, Xiaolong Liu
Summary: This study developed a strategy using red blood cells (RBCs) as carriers to deliver DNA vaccine encoding hepatocellular carcinoma (HCC) neoantigen, which effectively promoted neoantigen expression and induced T-cell immune response to prevent tumor growth. When combined with anti-PD-1, the vaccine achieved complete tumor regression and generated long-term tumor-specific immunological memory.
EMBO MOLECULAR MEDICINE
(2023)
Article
Environmental Sciences
Jiaoyun Zheng, Junyan Chen, Shuchao Wang, Dun Yang, Peng Zhou
Summary: In this study, a detailed single-cell analysis of HCC patients revealed strong correlations between gene expression levels and cellular characteristics, providing insights into the complexities of HCC progression and potential predictive genetic markers for drug response. The study also highlighted the pivotal role of ATP6V1G1 in apoptosis and migration in HCC cells.
ENVIRONMENTAL TOXICOLOGY
(2023)
Review
Immunology
Sihang Yu, Lei Zhou, Jiaying Fu, Long Xu, Buhan Liu, Yuanxin Zhao, Jian Wang, Xiaoyu Yan, Jing Su
Summary: There is increasing evidence showing the crucial role of the immune microenvironment, particularly the polarization state and function of macrophages, in the development of hepatocellular carcinoma. Tumor-derived exosomes in hepatocellular carcinoma act as information carriers and regulate the physiological state of cells in the microenvironment, thus controlling cancer progression. This review focuses on the role of exosome content in disease outcomes at different stages of hepatitis B virus/hepatitis C virus-induced hepatocellular carcinoma, and explores the mechanism by which macrophages contribute to hepatocellular carcinoma formation and the regulation of macrophage functions by the heterogeneity of exosome loading. The application prospects of exosome-based targeted drug delivery in immunotherapy research on hepatocellular carcinoma are also summarized.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Nanoscience & Nanotechnology
Mingxin Cao, Enyu Shi, Hanping Wang, Lujia Mao, Qiqi Wu, Xinming Li, Yanjie Liang, Xiaoying Yang, Yinsong Wang, Changyi Li
Summary: Oral squamous cell carcinoma (OSCC) is a common malignant tumor in the head and neck, and traditional treatment methods have limitations. Molecular targeted therapies offer solutions by maximizing anticancer efficacy and minimizing treatment toxicity. Receptor-mediated targeted delivery of anticancer therapeutics is the most promising approach.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Review
Oncology
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong, Dan Yi
Summary: This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma, discussing the effectiveness and safety of the combination to provide references for further application in clinical practice.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Lei Ding, Ping Zhang, Xu Huang, Kunmeng Yang, Xingkai Liu, Zhenxiang Yu
Summary: A responsive nanogel that can respond to intracellular reduction microenvironments has been developed for the treatment of hepatocellular carcinoma (HCC), showing excellent antitumor efficacy and minimal side effects.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce, Girolamo Ranieri
Summary: Hepatocellular carcinoma is the most common primary liver cancer with poor prognosis. New molecular targeted therapies have shown promising results in recent years. However, research into new treatments is still necessary.
Review
Oncology
Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu
Summary: Hepatocellular carcinoma (HCC) is a significant global health issue, and targeted therapy has made a breakthrough in treating advanced HCC. The combination of targeted therapy with immune checkpoint inhibitors shows more potent anticancer effects.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Meghan M. Bell, Nicholas T. Gutsche, A. Paden King, Kwamena E. Baidoo, Olivia J. Kelada, Peter L. Choyke, Freddy E. Escorcia
Summary: GPC3 is expressed in HCC, making it a promising therapeutic target, but GC33 alone has not shown therapeutic efficacy. Functionalizing the antibody with therapeutic radionuclides, such as Ac-225, may be a viable approach.
Article
Chemistry, Multidisciplinary
Sibei Lei, Xiaohua Chen, Yan Gao, Ming Shuai, Weilin Zhou, Jingmei Li, Jieping Wu, Ke Men, Xingmei Duan
Summary: mRNA-based gene therapy shows promise for treating hepatocellular carcinoma (HCC), but lacks precision in vivo. This study develops a novel HCC-specific peptide, HCC167, which can specifically recognize HCC cells and facilitate active targeting. When loaded with Bims-encoding mRNA, the HCC167-modified nanoparticles effectively suppress HCC progression in multiple models. The study also identifies the ALPPL2 protein as the specific binding receptor of the HCC167 peptide. This research demonstrates a potent active targeting strategy for mRNA-based HCC therapy.
ADVANCED FUNCTIONAL MATERIALS
(2022)
Review
Oncology
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele
Summary: One of the most important abilities of a tumor is to establish immunosuppression inside the tumor microenvironment. This is achieved through various mechanisms of tumor immune escape identified in experimental studies. In the liver, the microenvironment is oriented towards immune tolerance, preventing autoimmune reactions. Additionally, hepatocellular carcinoma often develops in the context of chronic inflammation. Due to these factors, different immunotherapeutic strategies have been developed and evaluated for advanced HCC. This review provides an overview of the clinical applications of immunotherapy for advanced HCC, including approved drugs and ongoing clinical trials.
Review
Biochemistry & Molecular Biology
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Anna Garmpi, Iason Psilopatis, Panagiotis Sarantis, Evangelos Koustas, Prodromos Kanavidis, Dionysios Prevezanos, Gregory Kouraklis, Michail Karamouzis, Georgios Marinos, Konstantinos Kontzoglou, Efstathios A. Antoniou
Summary: This review article discusses the characteristics of hepatocellular carcinoma (HCC) and presents the progress in HCC therapy through targeted therapies. The development of efficient molecular markers and alternative therapeutic targets are emphasized.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Engineering, Biomedical
Tingting Liu, Li Liu, Li Li, Jing Cai
Summary: Hepatocellular carcinoma (HCC) is a highly prevalent and deadly cancer, and there are many limitations in its surveillance, diagnosis, and treatment. In recent years, nanotechnology research has been focused on HCC, aiming to improve diagnosis accuracy and therapeutic effect.
MATERIALS TODAY BIO
(2023)
